Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
20.84
+1.53 (7.92%)
At close: Aug 4, 2026, 4:00 PM EDT
20.44
-0.40 (-1.92%)
After-hours: Aug 4, 2026, 7:34 PM EDT

Viridian Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.9170.850.30.311.772.96
Revenue Growth
201.99%23359.93%-3.82%-82.28%-40.20%182.19%
Gross Profit
0.9170.850.30.311.772.96
Operating Income
-385.7-363.4-299.04-254.45-134.3-79.73
Net Income
-360.59-342.6-269.95-237.73-129.87-79.41
Earnings Per Share
-3.32-3.32-3.07-3.91-2.71-6.66
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
762.18874.65717.58477.37424.55196.97
Total Debt
50.4449.9420.5820.214.650
Net Cash (Debt)
711.75824.71697457.17419.91196.97
Net Cash Growth
15.55%18.32%52.46%8.87%113.19%54.31%
Net Cash Per Share
7.919.7210.2710.2113.0916.53

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-303.39-276.39-232.32-184.17-184.17-93.84
Capital Expenditures
-0.43-0.5-0.51-0.9-0.9-0.8
Free Cash Flow
-303.82-276.89-232.83-185.07-185.07-94.64
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-42291.40%-512.91%-99018.20%-81035.00%-7579.23%-2690.79%
Pretax Margin
-37977.63%-483.57%-89387.09%-75711.46%-7079.23%-2669.52%
Profit Margin
-39538.40%-483.56%-89387.10%-75711.50%-7329.23%-2680.16%
FCF Margin
-33314.00%-390.81%-77096.00%-58938.90%-10444.00%-3193.89%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
32.4651.016326.313744.64680.90159.63